Free Trial

BioCryst Pharmaceuticals (BCRX) Stock Price, News & Analysis

BioCryst Pharmaceuticals logo
$8.41 -0.06 (-0.65%)
As of 01:23 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About BioCryst Pharmaceuticals Stock (NASDAQ:BCRX)

Key Stats

Today's Range
$8.30
$8.48
50-Day Range
$7.95
$10.10
52-Week Range
$6.01
$11.31
Volume
835,584 shs
Average Volume
3.73 million shs
Market Capitalization
$1.77 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.70
Consensus Rating
Moderate Buy

Company Overview

BioCryst Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
85th Percentile Overall Score

BCRX MarketRank™: 

BioCryst Pharmaceuticals scored higher than 85% of companies evaluated by MarketBeat, and ranked 179th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    BioCryst Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    BioCryst Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

  • Read more about BioCryst Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for BioCryst Pharmaceuticals are expected to grow in the coming year, from ($0.36) to ($0.07) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of BioCryst Pharmaceuticals is -46.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of BioCryst Pharmaceuticals is -46.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Growth Ratio

    BioCryst Pharmaceuticals has a PEG Ratio of 1.94. PEG Ratios above 1 indicate that a company could be overvalued.

  • Read more about BioCryst Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    12.99% of the float of BioCryst Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    BioCryst Pharmaceuticals has a short interest ratio ("days to cover") of 6.5.
  • Change versus previous month

    Short interest in BioCryst Pharmaceuticals has recently decreased by 3.36%, indicating that investor sentiment is improving.
  • Dividend Yield

    BioCryst Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    BioCryst Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.99% of the float of BioCryst Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    BioCryst Pharmaceuticals has a short interest ratio ("days to cover") of 6.5.
  • Change versus previous month

    Short interest in BioCryst Pharmaceuticals has recently decreased by 3.36%, indicating that investor sentiment is improving.
  • News Sentiment

    BioCryst Pharmaceuticals has a news sentiment score of 1.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for BioCryst Pharmaceuticals this week, compared to 7 articles on an average week.
  • Search Interest

    Only 5 people have searched for BCRX on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.
  • MarketBeat Follows

    Only 4 people have added BioCryst Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, BioCryst Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $595,700.00 in company stock.

  • Percentage Held by Insiders

    Only 5.10% of the stock of BioCryst Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    85.88% of the stock of BioCryst Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about BioCryst Pharmaceuticals' insider trading history.
Receive BCRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioCryst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BCRX Stock News Headlines

BioCryst to Present at Upcoming Investor Conference
Altucher: It Looks Like My Trump prediction is coming true
New Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Trump’s Great Gain” has officially begun. Altucher believes select cryptos could turn $900 into $108,000 over the next 12 months — and he’s laying out the full gameplan in a new presentation.tc pixel
BioCryst Announces Departure of Dr. Helen Thackray
See More Headlines

BCRX Stock Analysis - Frequently Asked Questions

BioCryst Pharmaceuticals' stock was trading at $7.52 at the beginning of the year. Since then, BCRX stock has increased by 11.8% and is now trading at $8.4050.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced its earnings results on Monday, August, 4th. The biotechnology company reported $0.15 EPS for the quarter, topping analysts' consensus estimates of $0.03 by $0.12. The firm's quarterly revenue was up 49.5% compared to the same quarter last year.
Read the conference call transcript
.

Top institutional shareholders of BioCryst Pharmaceuticals include State Street Corp (4.05%), Alkeon Capital Management LLC (2.72%), Geode Capital Management LLC (2.42%) and Arrowstreet Capital Limited Partnership (2.04%). Insiders that own company stock include Jon P Stonehouse, Yarlagadda S Babu, Helen M Thackray, Anthony Doyle, Nancy J Hutson, Theresa Heggie, Steven K Galson, Alan G Levin, Amy E Mckee, Machelle Sanders, Michael L Jones and Steve Aselage.
View institutional ownership trends
.

Shares of BCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that BioCryst Pharmaceuticals investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), Pfizer (PFE) and PayPal (PYPL).

Company Calendar

Last Earnings
8/04/2025
Today
8/29/2025
Next Earnings (Estimated)
11/03/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:BCRX
CIK
882796
Employees
530
Year Founded
1986

Price Target and Rating

High Price Target
$30.00
Low Price Target
$11.00
Potential Upside/Downside
+98.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.90
Research Coverage
10 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.18)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
1.94
Net Income
-$88.88 million
Net Margins
-6.41%
Pretax Margin
-5.77%
Return on Equity
N/A
Return on Assets
-1.78%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.25
Quick Ratio
2.22

Sales & Book Value

Annual Sales
$450.71 million
Price / Sales
3.92
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($2.01) per share
Price / Book
-4.19

Miscellaneous

Outstanding Shares
209,920,000
Free Float
199,214,000
Market Cap
$1.77 billion
Optionable
Optionable
Beta
1.10

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:BCRX) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners